Pouchitis Treatment Market by Treatment (Antibiotics, Immunosuppressive agents, Biologics and Others), by Distribution channel (Hospital pharmacies, Retail pharmacies and Online pharmacies): Global Opportunity Analysis and Industry Forecast, 2022-2031

The Pouchitis Treatment market was valued at $70million in 2022. It is projected to grow at a CAGR of 10.2% from 2023 to 2031 and reach more than 115 million by the end of 2031.  

Analysts’ Viewpoint by Cognate Lifesciences

The pouchitis treatment market is expected to grow due to increasing incidence of inflammatory bowel disease (IBD) and its association with pouchitis. Antibiotics and immunosuppressive agents are the first-line treatment for acute pouchitis, while biologic agents are reserved for refractory cases. There is also a growing interest in the use of complementary therapies, such as probiotics, fiber supplements, and anti-inflammatory agents, for the treatment of pouchitis. These alternative treatments may offer a more cost-effective and potentially safer option for patients who cannot tolerate or do not respond to conventional therapies.

However, the market faces challenges such as stringent regulatory requirements and the high cost of research and development. In addition, the lack of awareness about pouchitis among patients and healthcare professionals may hinder market growth.

The market is further driven by the increasing demand for innovative and effective treatments for pouchitis. Companies are investing in research and development activities to develop new therapies and expand their product portfolio. In addition, the rising geriatric population and increasing healthcare expenditure are expected to boost the growth of the pouchitis treatment market.

Pouchitis Treatment Overview 

Pouchitis is an inflammation of the ileal pouch, a surgically created reservoir that is used to replace the rectum in patients who have had their large intestine or colon removed due to ulcerative colitis or familial adenomatous polyposis. The ileal pouch is created by folding and stitching the small intestine to create a pouch that serves as a storage reservoir for stool.

The pouchitis treatment market is expected to grow in the coming years due to a combination of demographic, economic, and healthcare-related factors. One of the key drivers of market growth is the increasing incidence of inflammatory bowel disease (IBD), which is a common cause of pouchitis. According to the Crohn's and Colitis Foundation, IBD affects an estimated 3 million people in the United States alone. As the incidence of IBD continues to rise globally, so too will the incidence of pouchitis, which is a common complication of surgery for IBD.

The growing demand for effective and innovative treatments is another key driver of market growth. Patients and healthcare providers are increasingly seeking new and improved treatments for pouchitis that can improve quality of life and reduce the need for surgery or hospitalization. For example, some studies have shown that the use of biologic therapies such as infliximab and adalimumab can be effective in treating pouchitis in some patients. As more research is conducted and new therapies are developed, demand for pouchitis treatments is expected to increase.

Companies are also investing in research and development activities to develop new therapies and expand their product portfolio for the treatment of pouchitis. For example, Pfizer has developed a drug called tofacitinib, which is currently being studied for the treatment of pouchitis in patients with ulcerative colitis. Other companies are developing probiotics, fiber supplements, and other complementary therapies for the treatment of pouchitis, which is expected to contribute to market growth.

Increasing healthcare expenditure is also expected to contribute to market growth, as patients and healthcare providers have greater access to diagnostic tools and treatment options for pouchitis. For example, the development of advanced imaging technologies such as magnetic resonance enterography and capsule endoscopy has improved the diagnosis and management of pouchitis in some patients.

New product launches to flourish in the market

In May 2021 Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, announced the FDA approval of Stelara (ustekinumab) for the treatment of moderately to severely active ulcerative colitis, which can be a cause of pouchitis. In October 2020: Pfizer announced positive results from a Phase 3 trial of its drug tofacitinib for the treatment of ulcerative colitis, which can be a cause of pouchitis. The company is currently studying tofacitinib for the treatment of pouchitis in patients with ulcerative colitis.

Segment Overview:

By Treatment: The Pouchitis Treatment market is divided into Antibiotics, Immunosuppressive agents, Biologics and Others. Antibiotics are the most commonly used treatment for pouchitis, while immunosuppressive agents and biologics are reserved for more severe cases. Other treatments may include anti-inflammatory agents, probiotics, fiber supplements, and surgery in some cases. The market is expected to see growth in all segments, with biologics being the fastest growing segment due to their effectiveness in treating severe cases of pouchitis.

By Distribution Channel: The Pouchitis Treatment market is segmented by Hospital pharmacies, Retail pharmacies and online pharmacies. Hospital pharmacies are the primary distribution channel for pouchitis treatments, as many patients are diagnosed and treated while in the hospital. However, retail pharmacies and online pharmacies are also important distribution channels, as they allow patients to refill their prescriptions and receive ongoing treatment after they are discharged from the hospital. The online pharmacy segment is expected to see the fastest growth due to the convenience and accessibility of online ordering and delivery.

By Region:

The North American Pouchitis Treatment market is one of the largest markets globally. The region is characterized by high prevalence of inflammatory bowel disease (IBD), which is a major cause of pouchitis. The market is driven by factors such as increasing healthcare expenditure, rising geriatric population, and growing demand for effective and innovative treatments. The United States holds the largest share of the market in North America, owing to its high healthcare expenditure and advanced healthcare infrastructure. The market is dominated by the antibiotics segment, although the biologics segment is expected to see the fastest growth in the coming years due to their effectiveness in treating severe cases of pouchitis.

The Asia Pacific Pouchitis Treatment market is one of the fastest growing markets globally. The market is driven by factors such as increasing incidence of inflammatory bowel disease (IBD), rising geriatric population, and increasing healthcare expenditure in the region. The antibiotics segment dominates the market, although the biologics segment is expected to see the fastest growth in the coming years due to their effectiveness in treating severe cases of pouchitis. Countries such as India and China are expected to see significant growth in the market due to their large populations and high prevalence of IBD. The market is also seeing growth in online pharmacy sales due to the increasing adoption of e-commerce in the region.

Competitive analysis and profiles of the major players in the Pouchitis Treatment market, such as AstraZeneca, Teva Pharmaceutical Industries Ltd., Sebela Pharmaceuticals, Inc., Novartis AG

Pfizer Inc., Strides Pharma Science Limited, Tolmar Pharmaceuticals, Inc., Synergy Pharmaceuticals, Inc., LUPIN, Bausch Health, Sanofi and others. Major players have adopted product launch and acquisition as key developmental strategies to improve the product portfolio of the Pouchitis Treatment market.    

Market Scope and Structure Analysis

Key Segments Covered

Treatment

• Antibiotics
• Immunosuppressive agents
• Biologics
• Others

Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • Rest of Asia-Pacific
• LAMEA
  • Latin America
  • Middle East
  • Africa